TY - JOUR
T1 - Release of dopamine via the human transporter
AU - Eshleman, Amy J.
AU - Henningsen, Robert A.
AU - Neve, Kim A.
AU - Janowsky, Aaron
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1994/2
Y1 - 1994/2
N2 - A human dopamine transporter cDNA was cloned and transfected into COS-7 cells, a cell line that lacks vesicular storage and release mechanisms. Cells expressing the dopamine transporter acquired the capacity to take up and release dopamine via the transporter. Ionic conditions that stimulate inside- out transport in vivo, such as depolarizing concentrations of K+ or low concentrations of extracellular Na+, were found to stimulate Ca2+- independent release of [3H]dopamine from transfected COS-7 cells. Dopamine uptake inhibitors had one of three effects on transporter-mediated efflux. Some drugs, in addition to inhibiting uptake, inhibited spontaneous release of dopamine. Drugs in this class included mazindol, GBR-12935, bupropion, nomifersine, and benztropine. All of the drugs with the potential for abuse by humans either enhanced release (methamphetamine, amphetamine, and ethanol) or had no effect on release (phencyclidine, cocaine, and WIN 35,428). The ability to define classes of uptake blockers based on their effects on human transporter mediated dopamine efflux may lead to the identification of structural features of the transporter that differentiate abused from nonabused drugs.
AB - A human dopamine transporter cDNA was cloned and transfected into COS-7 cells, a cell line that lacks vesicular storage and release mechanisms. Cells expressing the dopamine transporter acquired the capacity to take up and release dopamine via the transporter. Ionic conditions that stimulate inside- out transport in vivo, such as depolarizing concentrations of K+ or low concentrations of extracellular Na+, were found to stimulate Ca2+- independent release of [3H]dopamine from transfected COS-7 cells. Dopamine uptake inhibitors had one of three effects on transporter-mediated efflux. Some drugs, in addition to inhibiting uptake, inhibited spontaneous release of dopamine. Drugs in this class included mazindol, GBR-12935, bupropion, nomifersine, and benztropine. All of the drugs with the potential for abuse by humans either enhanced release (methamphetamine, amphetamine, and ethanol) or had no effect on release (phencyclidine, cocaine, and WIN 35,428). The ability to define classes of uptake blockers based on their effects on human transporter mediated dopamine efflux may lead to the identification of structural features of the transporter that differentiate abused from nonabused drugs.
UR - http://www.scopus.com/inward/record.url?scp=0028158002&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028158002&partnerID=8YFLogxK
M3 - Article
C2 - 7906856
AN - SCOPUS:0028158002
SN - 0026-895X
VL - 45
SP - 312
EP - 316
JO - Molecular Pharmacology
JF - Molecular Pharmacology
IS - 2
ER -